Enfortumab vedotin plus pembrolizumab in advanced bladder cancer: hint of major added benefit. Patients for whom cisplatin-based therapy is unsuitable live significantly longer with the new drug combination than with previous therapy options.

Antibiotic resistance is a global health challenge that could overtake cancer mortality within a few decades. In a new study, researchers at Umeå University, Sweden, show that the emergence of resistance can be understood in the mechanism of how bacteria build up defences against being infected by viruses. It is about genes in the bacterium that interfere with the attacking virus's ability to multiply.

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center.